HIMS logo

Hims & Hers Health, Inc. Stock Price

NYSE:HIMS Community·US$8.2b Market Cap
  • 8 Narratives written by author
  • 12 Comments on narratives written by author
  • 1046 Fair Values set on narratives written by author

HIMS Share Price Performance

US$35.47
-28.75 (-44.77%)
US$173.02
Fair Value
US$35.47
-28.75 (-44.77%)
79.5% undervalued intrinsic discount
US$173.02
Fair Value
Price US$35.47
Deep_Insights US$173.02
AnalystConsensusTarget US$26.82
AdrianAnton US$50.07

HIMS Community Narratives

Fair Value
·
Fair Value US$173.02 79.5% undervalued intrinsic discount

Hims & Hers Health Multidimensional Revenue Expansion

10users have liked this narrative
0users have commented on this narrative
44users have followed this narrative
·
Fair Value US$26.82 32.2% overvalued intrinsic discount

Telehealth And Hormonal Health Will Transform Global Markets

12users have liked this narrative
0users have commented on this narrative
262users have followed this narrative
Fair Value
·
Fair Value US$50.07 29.2% undervalued intrinsic discount

Long on HIMS

0users have liked this narrative
0users have commented on this narrative
10users have followed this narrative
US$173.02
79.5% undervalued intrinsic discount
Fair Value
Revenue
36.3% p.a.
Profit Margin
10%
Future PE
60x
Price in 2030
US$242.66
US$50.07
29.2% undervalued intrinsic discount
Fair Value
Revenue
37% p.a.
Profit Margin
6.05%
Future PE
26.92x
Price in 2031
US$70.16
US$86.09
58.8% undervalued intrinsic discount
Fair Value
Revenue
22% p.a.
Profit Margin
15%
Future PE
50x
Price in 2030
US$138.65
US$17.15
106.8% overvalued intrinsic discount
Profit Margin
1%
Future PE
20x
Price in 2029
US$28.59
US$35
1.3% overvalued intrinsic discount
Revenue
19.45% p.a.
Profit Margin
8.65%
Future PE
29.7x
Price in 2029
US$42.72

Trending Discussion

Updated Narratives

HIMS logo

Hims & Hers Paves the Path to $1 Billion Quarterly Revenue in end of 2026

Fair Value: US$173.02 79.5% undervalued intrinsic discount
44 users have set this as their fair value
0 users have commented on this narrative
2 users have liked this narrative
HIMS logo

FY2025

Fair Value: US$29.21 21.4% overvalued intrinsic discount
5 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative
HIMS logo

Long on HIMS

Fair Value: US$50.07 29.2% undervalued intrinsic discount
10 users have set this as their fair value
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

High growth potential with mediocre balance sheet.

1 Risk
1 Reward

Hims & Hers Health, Inc. Key Details

US$2.4b

Revenue

US$641.8m

Cost of Revenue

US$1.7b

Gross Profit

US$1.7b

Other Expenses

-US$13.2m

Earnings

Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
-0.057
72.92%
-0.56%
218.3%
View Full Analysis

About HIMS

Founded
n/a
Employees
2442
CEO
Andrew Dudum
WebsiteView website
www.hims.com

Hims & Hers Health, Inc. operates as a consumer-first health and wellness platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, Canada, Germany, the Republic of Ireland, France, Spain, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides personalized health and wellness products; over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, skincare, sexual health and wellness, and hair care under the Hims & Hers brand name; and laboratory testing services to measure a set of biomarkers. Additionally, it offers medical consultation, post-consultation support services, and delivery of laboratory testing results services. Further, the company provides treatments and products for various chronic conditions related to hormone health, weight loss, dermatology, and mental health. The company offers its products through retail partnerships, in stores, and online. Hims & Hers Health, Inc. is based in San Francisco, California.

Recent HIMS News & Updates

Seeking Alpha Jun 18

Hims & Hers Health: Legal Risks Resolved With New International Growth Driver - Maintain Buy

Summary HIMS pivots to branded GLP-1 products, with it already driving robust engagement/subscriber growth while triggering the raised FY2026/reiterated FY2030 guidance. Strategic acquisitions in Canada/EU have driven the international revenue growth by +1,014% YoY, with further expansions likely from the Eucalyptus acquisition's $450M annual run-rate. These underscore HIMS' multi-pronged growth initiatives beyond the end-to-end manufacturing/personalized consumer health/lab testing capabilities, with future plans in diagnostics/wearables. Despite the lumpy profitability, the stock remains compelling at my estimated EV/EBITDA valuations of 24.54x and FY2030 EV/EBITDA valuations of 5.9x. HIMS is a Great Buy despite the recent recovery, albeit best suited for risk-tolerant investors due to the elevated short interest of 28.07%. Read the full article on Seeking Alpha
Analysis Article Jun 17

Hims & Hers Health (HIMS) Stock Could Be 81.8% Undervalued After Obesity Care Push

Hims & Hers Health (HIMS) stock is back in focus as investors react to its push into obesity care through FDA-approved treatments, a Novo Nordisk partnership, and a growing emphasis on peptide based metabolic health. See our latest analysis for Hims & Hers Health. Recent enthusiasm around obesity care, peptides, and new memberships has come alongside firm short term momentum in Hims & Hers Health stock. The 30 day share price return is 25.63%, yet the 1 year total shareholder return is still...

Recent updates

No updates